Severe Anemia and GI Bleeding in Hereditary Hemorrhagic Telangiectasia

Hereditary Hemorrhagic Telangiectasia (HHT) is a multisystem vascular disorder characterized by the development of telangiectasias—small, dilated blood vessels—that can lead to chronic bleeding and severe complications. A recent case report published by Cureus highlights the critical nature of this condition in a young adult, where gastrointestinal arteriovenous malformations and pulmonary arteriovenous malformations contributed to severe, transfusion-dependent anemia.

The manifestation of HHT varies across patients, but telangiectatic bleeding is the most common and significant feature of the disorder. This bleeding primarily occurs in the form of recurrent epistaxis (nosebleeds) and chronic gastrointestinal (GI) bleeding, which can result in substantial psychosocial morbidity and severe iron deficiency anemia.

Gastrointestinal Bleeding and Anemia

Gastrointestinal bleeding develops in approximately 30% of patients with HHT. In these cases, the bleeding is typically chronic, low-grade, and occurs in an intermittent fashion. However, the cumulative effect of this blood loss, often combined with epistaxis, can lead to profound anemia.

Anemia affects approximately half of all HHT patients. In up to 25% of these cases, the anemia is classified as severe. For some patients, this progresses to transfusion-dependent anemia, requiring regular blood transfusions to maintain stable hemoglobin levels.

Diagnostic Approaches and Guidelines

The Second International HHT Guidelines (2020) provide specific recommendations for the testing, diagnosis, and management of HHT-related gastrointestinal bleeding. The expert panel recommends esophagogastroduodenoscopy (EGD) as the first-line diagnostic test for suspected bleeding.

The guidelines emphasize specific screening protocols based on the patient’s genetic profile:

• Patients with SMAD4-HHT, or those suspected of having it, should undergo screening colonoscopies starting at age 15.
• For SMAD4-HHT patients, colonoscopies should be repeated every three years if no polyps are found.
• If colonic polyps are detected, colonoscopies should be performed every year in conjunction with EGD.
• Patients with other forms of HHT who do not have the SMAD4 mutation should follow general population guidelines for colorectal cancer screening.

Clinicians are advised to exercise caution when performing EGDs in inexperienced centers due to the risk of unusual complications, such as massive epistaxis, and must be aware of necessary precautions for patients who also possess pulmonary arteriovenous malformations (AVMs).

Multisystem Vascular Impact

HHT is not limited to the gastrointestinal tract. The disorder affects the vascular structure of numerous organs. Pulmonary arteriovenous malformations are a significant concern, as they can complicate the management of other symptoms and influence the safety of certain medical procedures.

The combination of mucocutaneous telangiectasias, pulmonary AVMs, and GI bleeding creates a complex clinical picture. The resulting iron deficiency anemia can be severe, impacting the overall quality of life and requiring intensive medical intervention to manage blood loss and maintain systemic health.